Sign in

    Robert Hazlett

    Research Analyst at BTIG

    Robert Hazlett's questions to RedHill Biopharma (RDHL) leadership

    Robert Hazlett's questions to RedHill Biopharma (RDHL) leadership • Q3 2021

    Question

    Robert Hazlett of BTIG asked for anecdotal evidence regarding the sales force's traction with Talicia and whether the market for diagnosing H. pylori was improving. He also requested a revenue breakdown between Movantik and Talicia for the quarter.

    Answer

    SVP of Sales and Marketing Rob Jackson confirmed that field traction for Talicia is improving, with better execution and more consistent growth, and noted that diagnostic conditions have improved since the peak of the pandemic. CFO Micha Ben-Chorin provided the revenue breakdown, stating that Movantik contributed a little over $19 million and Talicia contributed almost $2.25 million in the quarter.

    Ask Fintool Equity Research AI

    Robert Hazlett's questions to RedHill Biopharma (RDHL) leadership • Q2 2021

    Question

    Robert Hazlett asked if the upcoming opaganib Phase 2/3 results could lead to an Emergency Use Authorization (EUA), questioned its manufacturing status, inquired about the I-SPY trial data timeline, the reason for increased R&D spending, and future investment in the prostate cancer program.

    Answer

    COO Gilead Raday stated that the opaganib data will determine the regulatory path, including a potential EUA, and that scaled-up manufacturing is being prepared. CEO Dror Ben-Asher noted it's too early for an I-SPY timeline but expects rapid enrollment. CFO Micha Ben-Chorin attributed higher R&D spend to COVID-19 and NTM programs. COO Gilead Raday confirmed continued development of opaganib in oncology pending full data.

    Ask Fintool Equity Research AI